期刊文献+

IIVP方案治疗复发难治高危弥漫大B细胞淋巴瘤1O例 被引量:1

原文传递
导出
摘要 目的探讨IIVP方案【去甲氧柔红霉素(IDA)、异环磷酰胺(IFO)、依托泊苷(VP16)]治疗复发难治、高危弥漫大B细胞淋巴瘤的治疗效果。方法IFO1g/m^2,静脉滴注,第1天至第5天,配合巯乙磺酸钠400mg/次.0、3、6、9h静脉推注4次,IDA10mg/m^2,静脉推注,第1天至第2天,VP16 150mg/m^2,静脉滴注,第1天至第3天,每4周重复,每疗程后进行疗效评价。结果复发难治、高危弥漫大B细胞淋巴瘤10例,完全缓解(CR)2例,不确定的完全缓解(CRu)2例,部分缓解(PR)3例,有效率(CR+CRu+PR)70%。结论IIVP方案治疗复发难治、高危弥漫大B细胞淋巴瘤可取得较高的缓解率,并为白体干细胞移植创造条件,进一步提高此类患者的治疗效果。
出处 《白血病.淋巴瘤》 CAS 2008年第6期448-449,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献5

  • 1张之南,沈悌.血液病疗效及诊断标准[M].北京:科学出版社,2007:224.
  • 2OyanB, Koc Y, OzdemirE, et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory hodgkin or non-Hodgkin lymphoma:a salvage regimen with high response rates before autologous stem cell transplantation [J]. Biology of Blood and Marrow Transplantation II, 2005, 11 (9): 688-697.
  • 3Abali H, Oyan B, Koc Y, et al. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation[J]. Am J Clin Oncol, 2005, 28(3): 264-269.
  • 4赵淑清,李军民,沈志祥.去甲氧柔红霉素在血液肿瘤治疗中的应用[J].中华血液学杂志,2006,27(1):68-70. 被引量:12
  • 5Bishton M J, Lush R J, Byrne JL, el al. Ifosfamide,etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobihsation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease [J]. Br J Haematol, 2007, 136(5): 752-761.

共引文献15

同被引文献8

  • 1Dredge K, Horsfall R, Rcbinson SP, et al. Orally administered lenalidomide(CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro[J]. Microvasc Res, 2005, 69(1-2): 56-63.
  • 2Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies[J]. J Hematol Oncol, 2009, 2(36): 1-10.
  • 3Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia[J]. Blood, 2008, 111(11): 5291-5297.
  • 4Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells[J]. Cancer Res, 2007, 67(2): 746-755.
  • 5Vallet S, Palumbo A, Raje N, et al. Thalidomide and lenalidomide:mechanism-based potential drug combinations[J]. Leuk Lymphoma, 2008, 49(7): 1238-1245.
  • 6Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2008, 26(30): 4952-4957.
  • 7Witzig TE, Vose JM, Zinzani PL, et al. An international phase Ⅱtrial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma[J]. Ann Oncol, 2011, 22(7): 1622-1627.
  • 8路瑾,黄晓军.来那度胺在血液恶性肿瘤中的应用[J].中华内科杂志,2013,52(9):777-780. 被引量:4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部